Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325685 | 0.83 | NPSR1 (0.44) | NPSR1KDM4EHPGDTSHRALDH1A1 | |
| SCHEMBL6037528 | 0.82 | ALOX5 (0.42) | ALOX5KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL5804157 | 0.82 | TDP1 (0.41) | NPSR1KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL27886540 | 0.81 | TSHR (0.44) | NPSR1ALOX5KDM4EHPGDTSHR | |
| SCHEMBL8392334 | 0.81 | NPSR1 (0.43) | NPSR1KDM4EHPGDTSHRALDH1A1 | |
| SCHEMBL4131826 | 0.81 | NPSR1 (0.43) | NPSR1KDM4EHPGDTSHRALDH1A1 | |
| SCHEMBL9505872 | 0.81 | KMT2A (0.46) | NPSR1KDM4EHPGDTSHRALDH1A1 | |
| SCHEMBL28031723 | 0.80 | NPSR1 (0.39) | NPSR1ALOX5KDM4EHPGDTSHR | |
| SCHEMBL8493070 | 0.80 | KMT2A (0.41) | NPSR1KDM4EHPGDTSHRALDH1A1 | |
| SCHEMBL2895073 | 0.80 | CA1 (0.31) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256452-A1 | INHIBITORS OF NECROPTOSIS | Catalyst Therapeutics Pty Ltd. (AU) | 2017-12-20 | — | — | EP | disclosed |
| CN-106928098-A | A kind of synthetic method of indoxacarb intermediate semicarbazone | 江苏优嘉植物保护有限公司 | 2017-07-07 | — | — | CN | disclosed |
| WO-2016127213-A1 | INHIBITORS OF NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2016-08-18 | — | — | WO | disclosed |
| EP-2858501-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013176970-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0535184-A1 | NOVEL QUINOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | BOUCHARA S.A. (FR) | 1993-04-07 | — | — | EP | disclosed |
| EP-0533895-A1 | NOVEL QUINOLONES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOUCHARA S.A. (FR) | 1993-03-31 | — | — | EP | disclosed |
| WO-1992017466-A1 | NOVEL QUINOLONES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOUCHARA S.A. (FR) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992015574-A1 | NOVEL QUINOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | BOUCHARA S.A. (FR) | 1992-09-17 | — | — | WO | disclosed |
| EP-0154969-A2 | Piperazine derivatives and their acid addition salts | MITSUBISHI KASEI CORPORATION (JP) | 1985-09-18 | — | — | EP | disclosed |
| US-4046797-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPSR1 1439/4885ALOX5 124/4885KDM4E 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.